Drug Discovery Today

FEBRUARY 16, 2021

Celltrion is on track developing a neutralising antibody cocktail with Regdanvimab (CT-P59) tailored to fight against the emerging new variants. CT-P59 demonstrated neutralising capability against key emerging mutations, including the UK variant in addition to six variant genome mutations of SARS-CoV-2.

Antibody 45

Antibody Development Genome Genomics 45

XTalks

SEPTEMBER 30, 2020

The research shows that the activity of the immune messenger type 1 interferon (IFN) protein is diminished, either by genetic mutations or an autoimmune attack by neutralizing antibodies against it, in a subset of COVID-19 patients. These rogue antibodies blocked interferon action and were not present in patients with mild COVID-19 cases.

Antibody 135

Antibody Genetics Research In-Vitro 135

Pharmaceutical Technology

MAY 12, 2023

The collaboration will use the integrated drug creation platform of Absci and the clinical immunology datasets from the Kennedy Institute to identify antibodies to immune-mediated inflammatory diseases and autoimmune conditions with unprecedented speed.

Development 130

Development Antibody Immune Response Genome 130

BioSpace

JUNE 7, 2022

Financing rounds will support platforms for tumor-targeting antibodies, genome-scale nucleic and acid imaging. Funding this week went mostly to companies with sophisticated tech platforms.

Genome 97

Genome Genomics Antibody 97

The Pharma Data

NOVEMBER 26, 2020

26, 2020 /PRNewswire/ — BASE10 Genetics and DNA Link today announced their collaboration on a research project to evaluate the usability of DNA Link ‘ s AccuFind COVID-19 IgG antibody test in a healthcare setting. Study will expand access to antibody testing outside of laboratory settings. CHICAGO , Nov.

DNA 52

DNA Antibody Research Genome 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 162

In-Vivo Genome Genomics Gene Editing 162

The Pharma Data

SEPTEMBER 11, 2021

Boehringer Ingelheim believes Twist’s ability to generate potent, diverse therapeutic antibodies by mining its comprehensive libraries, combined with our extensive capabilities and experience in drug discovery and development, will enable us to deliver breakthrough opportunities to patients,” said Clive R. About Twist Bioscience Corporation.

Antibody 52

Antibody DNA Containment Manufacturing 52

The Pharma Data

JUNE 2, 2022

Boehringer Ingelheim and the Agency for Science, Technology and Research (A*STAR) today announced a global licensing agreement under which Boehringer Ingelheim will obtain exclusive worldwide rights to research, develop and commercialize products based on a panel of innovative, tumor-specific antibodies from A*STAR.

Antibody 52

Antibody Licensing Licensing Development 52

Drug Discovery World

MARCH 25, 2024

Ricoh and ERS Genomics Ricoh has signed a non-exclusive licensing agreement in the USA and Japan with ERS Genomics for access to the company’s foundational CRISPR/Cas9 genome editing technology patents. Together, we can leverage our unique strengths to realise a future where AI and genetics revolutionise healthcare.”

Gene Editing 52

Gene Editing Drugs Genome Genomics 52

Pharmaceutical Technology

FEBRUARY 15, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. These animals have been used as a key tool in functional genomics to generate models for human diseases and to validate new drugs.

Genetics 130

Genetics DNA Antibody Genome 130

The Pharma Data

DECEMBER 17, 2020

MacroGenics, a biopharma company working to make cancer history with the development of innovative monoclonal antibody-based therapeutics, had its first product , MARGENZA , approved by the FDA on Wednesday. The new two-hour infusion time was previously approved by the European Medicines Agency (EMA) in May 2020.

FDA Approval 52

FDA Approval Genome Genomics Production 52

pharmaphorum

OCTOBER 4, 2022

AstraZeneca’s rare disease firm Alexion is set to expand its genomic medicine portfolio with the acquisition of gene editing specialist LogicBio Therapeutics, in a deal worth approximately $68 million. The LogicBio deal is the latest in a string of acquisitions for AstraZeneca.

Gene Editing 62

Gene Editing Gene Genome Genomics 62

The Pharma Data

OCTOBER 9, 2021

Roche (SIX RO, ROG; OTCQX RHHBY) now posted that gantenerumab, ananti-amyloid beta antibody developed for subcutaneous administration, has been granted Improvement Rectifier Designation by theU.S. Food and Drug Administration (FDA) for the treatment of people living with Alzheimer’s fever ( Notice). Source link: [link].

Antibody 52

Antibody In-Vitro Trials Development 52

Drug Discovery World

FEBRUARY 12, 2024

Kishen Chahwala, PhD, Business Development Manager, Enhanc3D Genomics “AI is transforming the way we fight cancer by unlocking the secrets of large and complex datasets. It is becoming more broadly acknowledged that AI is set to transform one of the most promising yet under-utilised fields of omics – 3D genomics.

Genome 139

Genome Genomics Life Science Gene Therapy 139

pharmaphorum

MARCH 24, 2022

The examples remain few and far between, however, as in recent decades the pharma industry has turned its attention to synthetic molecules and biologics like antibodies. The platform uses an artificial intelligence (AI) algorithm to zero in on the genes encoding natural products based on their computationally predicted human target.

Medicine 98

Medicine Genome Genomics Engineer 98

Drug Discovery World

MARCH 27, 2023

Macomics and Ono Pharmaceutical have entered a worldwide drug discovery collaboration agreement to develop new immuno-oncology antibody drugs against a novel macrophage target of interest in cancer. Macrophages (TAMs) are often the most abundant immune cell and modulating TAMs can enhance the body’s ability to fight cancer.

Drugs 52

Drugs Antibody Genome Genomics 52

Drug Discovery World

APRIL 8, 2024

Aviv Regev, Head and Executive Vice President of Research and Early Development at Genentech, opened the session with a discussion of how advances in genomic sequencing are fostering the development of data-rich cell atlases and what that data could mean for new insights into cancer biology and novel therapeutics.

In-Vivo 52

In-Vivo In-Vitro Antibody Protein 52

Pharmaceutical Technology

FEBRUARY 3, 2023

The field of genomic medicine has reached a true turning point. Moving the viral vector field closer to the monoclonal antibody field is really what we see as the way forward.” More efficient, suspension-based cell culture processes are urgently needed in the now fast-developing genomic medicine space.

Genome 244

Genome Genomics Medicine Gene Therapy 244

Drug Discovery World

DECEMBER 21, 2023

Other biotechnologies coming to the fore this year were antibody-drug conjugates and CRISPR gene editing. Three trends in the antibody-drug conjugate (ADC) market Antibody-drug conjugates are biopharmaceutical products in which a monoclonal antibody (mAB) is linked to a small molecule drug with a stable linker.

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

The Pharma Data

OCTOBER 14, 2021

Roche announced that gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, has been granted Breakthrough Therapy Designation by the U.S. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

Antibody 52

Antibody Medicine In-Vitro Trials 52

Pharmaceutical Technology

MARCH 9, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

In-Vivo 130

In-Vivo Antibody Genetics Gene 130

Pharmaceutical Technology

FEBRUARY 14, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin 1, which are now well established in the industry.

In-Vivo 130

In-Vivo DNA Antibody Gene 130

Drug Discovery World

MARCH 13, 2024

In 2019 he was part of a research team which discovered humanised antibody, PRL3-zumab, was effective at shrinking PRL3 over-expressing tumours, and which has since been approved for Phase II clinical trials in Singapore, the US and China. There has also been significant investment in infrastructure in the country.

Life Science 69

Life Science Genome Genomics Research 69

Drug Discovery World

OCTOBER 5, 2023

The presentations will be followed by a panel discussion addressing new drug discovery and development concepts and tools in cancer research, and how these new approaches – e.g. engineered proteins, antibodies, micro RNA, nanocarriers, antibody drug conjugates – can help address unmet need in oncology. More to be announced.

Research 52

Research Antibody Medicine RNA 52

Drug Discovery World

JUNE 22, 2023

This has been demonstrated to be an effective way to improve AAV delivery, to increase the breadth of expression in pre-clinical models, and to shield AAVs from neutralising antibodies. “We

Gene Therapy 52

Gene Therapy Gene Editing Drug Delivery Gene 52

XTalks

JUNE 16, 2023

Cetuximab, an anti-epidermal growth factor receptor (anti-EGFR) antibody with FDA approval for metastatic colorectal cancer, is effective in conjunction with encorafenib. A negative result from a plasma specimen does not rule out genomic findings in a patient’s tumor. ” What is FoundationOne Liquid CDx?

FDA Approval 97

FDA Approval Genome Genomics DNA 97

Pharmaceutical Technology

JULY 5, 2022

On leaving the liver cells, the virus hijacks bits of cell membrane and conceals itself from antibodies that would have isolated the virus before it travelled far through the bloodstream. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.

Protein 130

Protein RNA Genome Genomics 130

Drug Discovery World

MAY 25, 2023

Gyros Protein Technologies: Gyrolab Generic Cyno Anti-Drug Antibodies (ADA) Kit Reagents The kit reagents are for the detection of circulating immune complexes of human IgG with cyno anti-human IgG.

Production 52

Production Reagent DNA Drugs 52

Drug Discovery World

NOVEMBER 27, 2023

As the significance of large molecules continues to broaden across diverse modalities, emphasis on bispecific and multispecific antibodies to treat various disorders such as rheumatologic diseases, cancer, diabetes, anaemia, and infectious diseases becomes paramount. References Mistry RK, Kelsall E, Sou SN, et al.

Production 59

Production Engineer Gene Editing Gene 59

Pharmaceutical Technology

MAY 8, 2023

Adeno-associated virus vectors, alcohol dehydrogenase compositions, and antibody serum stabilisers are some of the accelerating innovation areas, where adoption has been steadily increasing. Among maturing innovation areas are anti-influenza antibody compositions and anti-interleukin-1, which are now well established in the industry.

Antibody 147

Antibody Vaccination Vaccine Dermatology 147

Drug Discovery World

MARCH 26, 2024

For example, progress made in developing gene mutant-specific inhibitors, antibody-drug conjugates (ADC), or cellular therapies.

RNA 64

RNA In-Vivo In-Vitro DNA 64

Pharmaceutical Technology

JUNE 24, 2022

1 variant, on 22 June, Moderna said its booster also showed a “potent” antibody response against Omicron subvariants BA.4 Given SARS-CoV-2’s ability to mutate and change its genome, it is hard to say what will be the future variants of the virus. In addition to providing protection against the Omicron BA.1 1 variant of concern.

Vaccination 264

Vaccination Vaccine Antibody Medicine 264

Drug Discovery World

NOVEMBER 14, 2023

Participants include: Michael Seiler, Vice President of Commercial Products, Taconic Biosciences Spiro Rombotis, CEO, Cyclacel Joseph Peterson, CTO & Co-founder, SimBioSys Xueming Qian , CEO of Transcenta Michael Seiler Spiro Rombotis Joseph Peterson Xueming Qian Thereafter, we will have the following presentations: Qasim Ahmad, CMO (..)

Research 52

Research Genome Genomics Antibody 52

Pharmaceutical Technology

DECEMBER 9, 2022

In regards to the latter, notable examples include the acquisition of Cergentis, a genomics-focused biotechnology company based in the Netherlands. The deal allows the company to provide proprietary technology and knowledge steeped in fast-evolving genomic techniques that support effective decision-making and R&D program design.

Development 130

Development Manufacturing Production Vaccination 130

Drug Discovery World

NOVEMBER 2, 2023

Participants include: Michael Seiler, Vice President of Commercial Products, Taconic Biosciences Spiro Rombotis, CEO, Cyclacel Joseph Peterson, CTO & Co-founder, SimBioSys Xueming Qian , CEO of Transcenta Michael Seiler Spiro Rombotis Joseph Peterson Xueming Qian Thereafter, we will have the following presentations: Qasim Ahmad, CMO (..)

Research 52

Research Genome Genomics Medicine 52

Drug Discovery World

JULY 10, 2023

Think how cell and gene therapies or monoclonal antibodies have become targeted medicines for cancer and you’ll get an idea of the shifting pharmaceutical market. Its convergence with genomics makes sense and we have now multiple examples of AI being used to inform prescribing, diagnostics and drug discovery/ development.

Gene Therapy 52

Gene Therapy Gene Scientist Gene Editing 52

The Pharma Data

OCTOBER 14, 2020

Food and Drug Administration (FDA) to begin a Phase I clinical trial of hAd5-COVID-19, the company’s novel COVID-19 vaccine candidate that targets both the inner nucleocapsid (N), engineered to activate T cells, and outer spike (S) protein, engineered to activate antibodies against the coronavirus (SARS-CoV-2).

Antibody 52

Antibody Vaccination Vaccine Trials 52